BETAGEN 8MG 50TAB

Indications

Approved Uses

Treatment of Ménière’s syndrome/disease and associated symptoms (vertigo, tinnitus, fluctuating hearing loss; may include nausea).

Off-Label Uses

Off-label: symptomatic treatment of other vestibular disorders/vertigo (e.g., peripheral vestibular vertigo) where clinically appropriate; migraine/motion-sickness uses are not well established.

Dosage & Administration

Dosing by Condition

Ménière’s syndrome: 8-16 mg three times daily initially; maintenance usually 24-48 mg/day in divided doses; typical maximum 48 mg/day.

Initial Dose

8-16 mg three times daily

Maintenance Dose

24-48 mg per day in 2-3 divided doses

Maximum Dose

48 mg per day

Children's Dosage

Not approved for children under 18 years

Dose Adjustment Notes

No routine dose adjustment is generally required in elderly patients or in renal/hepatic impairment, but evidence is limited-use clinical caution and titrate to response; use caution in patients with peptic ulcer disease and asthma.

How to Take

Oral: swallow the tablet with water; take with or after food to reduce gastrointestinal upset; take in divided doses at regular intervals as prescribed.

Side Effects

Common Side Effects

Nausea, dyspepsia/indigestion, headache; may include abdominal pain/bloating.

Side Effect Frequency

Common (≥1/100 to <1/10): headache, nausea, dyspepsia; Not known: hypersensitivity reactions (including rash, pruritus, urticaria, angioedema, anaphylaxis) and other GI complaints (e.g., vomiting, abdominal pain, bloating).

Safety & Warnings

Contraindications

Phaeochromocytoma; hypersensitivity to betahistine (betahistine dihydrochloride) or any excipient.

Warnings & Precautions

Use caution in bronchial asthma; peptic ulcer disease or history of ulcer/dyspepsia; and in patients with allergic conditions (e.g., urticaria, rash, allergic rhinitis). Therapeutic benefit may take days to weeks; concomitant antihistamines may reduce effect.

Age Restriction

Not recommended under 18 years.

Drug Interactions

Drug Interactions

MAO inhibitors (including MAO-B selective agents such as selegiline) may increase betahistine exposure-use caution; antihistamines may theoretically antagonize betahistine’s effect (clinical significance uncertain).

Interaction Severity

MODERATE: MAO inhibitors (including MAO-B selective) may inhibit betahistine metabolism and increase exposure; H1 antihistamines may reduce betahistine effect via pharmacodynamic antagonism (clinical significance variable).

Food Interaction

Food has little effect on absorption; may be taken with or without food

Special Populations

Children

Not approved for children under 18 years

Elderly

Standard adult dosing. Although data is limited, extensive post-marketing experience suggests no dose adjustment is necessary.

Liver Impairment

No specific dose adjustment recommended; limited data-use caution in hepatic impairment.

Storage & Patient Advice

Stopping the Medicine

Do not stop unless advised by the prescriber; if stopped, vertigo/tinnitus symptoms may recur-no taper is generally required.

Overdose

Symptoms: nausea, vomiting, dyspepsia/abdominal pain, somnolence/drowsiness, ataxia; seizures/convulsions reported with very high doses (and more severe cardio‑pulmonary complications reported rarely, especially with co-ingestants). Management: no specific antidote-supportive/symptomatic care; consider activated charcoal if recent ingestion and seek urgent medical attention.

Monitoring Requirements

No routine laboratory monitoring; monitor clinically for worsening bronchial asthma and for gastrointestinal symptoms/recurrence in patients with current or past peptic ulcer disease.

Pharmacology

Mechanism of Action

Partial agonist at histamine H1 receptors and antagonist at histamine H3 receptors, increasing histamine turnover/release and improving inner-ear microcirculation while facilitating central vestibular compensation (mechanism not fully established).

Onset of Action

Improvement is often seen after ~2 weeks; best/maximum benefit may take several weeks to a few months of continuous therapy.

Duration of Effect

Symptom control is maintained only with continuous regular dosing; maximal benefit often requires weeks to months of ongoing therapy.

Half-Life

Elimination half-life is typically reported for the metabolite 2‑PAA at ~3-4 hours (≈3.5 hours).

Bioavailability

Readily and almost completely absorbed after oral administration (rapid absorption).

Metabolism

Rapid and extensive metabolism (primarily oxidative deamination) to inactive 2‑pyridylacetic acid (2‑PAA); MAO involvement is described, but not typically framed as a specific hepatic CYP pathway.

Excretion

Primarily renal: ~85-90% (often reported up to >90%) excreted in urine within 24 hours mainly as the inactive metabolite 2‑pyridylacetic acid (2‑PAA); minimal unchanged drug.

Product Information

Available Dosage Forms

Tablet (8 mg) for oral use.

Composition per Dose

Each tablet: 8 mg betahistine dihydrochloride

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Primary Use

Used for the treatment of Ménière's disease symptoms, which include vertigo (dizziness and spinning sensation), tinnitus (ringing in the ears), and hearing loss.

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.